Microbot Medical (NASDAQ:MBOT)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Wednesday, AnalystRatings.com reports. They presently have a $10.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 56.49% from the company’s current price.

The analysts wrote, “Our price target is derived from an estimated market value of the firm at $60M, which includes a discounted cash flow (DCF)-based asset value of SCS, assuming 60% probability of approval, 20% discount rate and 2% terminal growth rate.””

Separately, ValuEngine downgraded shares of Microbot Medical from a “buy” rating to a “hold” rating in a research report on Tuesday.

Shares of Microbot Medical stock traded up $0.09 during trading on Wednesday, reaching $6.39. The company had a trading volume of 810 shares, compared to its average volume of 199,295. The company has a market cap of $27.57 million, a price-to-earnings ratio of -2.60 and a beta of 5.04. The firm’s fifty day moving average is $5.99 and its 200-day moving average is $6.56. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.69 and a current ratio of 2.69. Microbot Medical has a fifty-two week low of $1.38 and a fifty-two week high of $19.40.

Microbot Medical (NASDAQ:MBOT) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09. On average, research analysts anticipate that Microbot Medical will post -1.33 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in MBOT. Geode Capital Management LLC bought a new stake in shares of Microbot Medical during the 4th quarter valued at about $38,000. Renaissance Technologies LLC grew its position in shares of Microbot Medical by 5.5% during the 2nd quarter. Renaissance Technologies LLC now owns 206,887 shares of the biotechnology company’s stock valued at $1,065,000 after buying an additional 10,838 shares during the last quarter. BlackRock Inc. grew its position in shares of Microbot Medical by 5.7% during the 2nd quarter. BlackRock Inc. now owns 183,520 shares of the biotechnology company’s stock valued at $945,000 after buying an additional 9,906 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Microbot Medical during the 2nd quarter valued at about $45,000. Finally, Morgan Stanley grew its position in shares of Microbot Medical by 77.0% during the 2nd quarter. Morgan Stanley now owns 6,316 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 2,748 shares during the last quarter. 14.79% of the stock is owned by institutional investors and hedge funds.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.

Featured Story: What Are Treasury Bonds?

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.